Journal of Enzyme Inhibition and Medicinal Chemistry最新文献

Identification of the first peptide inhibitor of UBE2C enzymatic activity: insights from metadynamics-guided folding and binding studies. 第一个UBE2C酶活性肽抑制剂的鉴定：来自元动力学指导的折叠和结合研究的见解。

IF 5.4 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-01-06 DOI: 10.1080/14756366.2025.2605383

Luciano Pirone, Bianca Fiorillo, Annarita Del Gatto, Rita Russo, Alessandra Guarracino, Chiara Cassiano, Laura Zaccaro, Federica Moraca, Emilia Pedone, Bruno Catalanotti

引用次数: 0

Cynanchum wilfordii modulates inflammatory responses in LPS-stimulated RAW264.7 cells via the NF-κB and MAPK pathways. 雷公藤通过NF-κB和MAPK通路调节lps刺激的RAW264.7细胞的炎症反应。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-01-22 DOI: 10.1080/14756366.2025.2568085

Yun-Jeong Ji, Min Hye Kang, Sin Hee Han, Young-Seob Lee, Myoung-Jin Kim, Jang Hoon Kim, Gwi Yeong Jang

{"title":"Cynanchum wilfordii modulates inflammatory responses in LPS-stimulated RAW264.7 cells via the NF-κB and MAPK pathways.","authors":"Yun-Jeong Ji, Min Hye Kang, Sin Hee Han, Young-Seob Lee, Myoung-Jin Kim, Jang Hoon Kim, Gwi Yeong Jang","doi":"10.1080/14756366.2025.2568085","DOIUrl":"10.1080/14756366.2025.2568085","url":null,"abstract":"Cynanchum wilfordii is a widely used herb in Oriental medicine, known for its wide range of therapeutic applications. The present study was conducted with the aim of evaluating the effects of selected compounds isolated from C. wilfordii, including 4-hydroxyacetophenone (CW1), 2,4-dihydroxyacetophenone (CW2), wilfoside K1N (CW3), and cynandione A (CW4), on the inflammatory response induced by treatment of macrophages with LPS. The study focused on the analysis of the MAPK and NF-κB pathways. The results showed that treatment with CW1, CW2, CW3 and CW4 inhibited the expression of p-ERK, p-JNK, p-p38 and p-IkBa in LPS-induced macrophages, with CW4 exhibiting the greatest inhibitory effects. Furthermore, CW4 treatment showed the most significant inhibitory effect on p-IκB-α/IκB-α expression in the NF-κB pathway. In conclusion, the data demonstrate that CW4 exerts a robust inhibitory effect on macrophage inflammatory signalling pathways in the LPS-induced inflammatory response.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2568085"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12829426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs. fda批准的含吲哚药物的合成策略和治疗见解。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-01-27 DOI: 10.1080/14756366.2026.2616556

Tengjiao Yang, Yanfeng Zhang, Peng Liu, Peng Qi, Xiankai Li, Wubin Zhi, Lijie Zhao

{"title":"Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs.","authors":"Tengjiao Yang, Yanfeng Zhang, Peng Liu, Peng Qi, Xiankai Li, Wubin Zhi, Lijie Zhao","doi":"10.1080/14756366.2026.2616556","DOIUrl":"10.1080/14756366.2026.2616556","url":null,"abstract":"Indole is a privileged heteroaromatic scaffold in medicinal chemistry, characterised by its unique physicochemical properties, hydrogen-bonding potential, and bioisosteric versatility. Over the past decades, numerous indole-containing drugs have been approved by the Food and Drug Administration (FDA), spanning diverse therapeutic areas including oncology, infectious diseases, gastrointestinal disorders, neurological conditions, and cardiovascular diseases. This review provides a comprehensive survey of FDA-approved indole-based drugs, with particular emphasis on those approved from 2013 to the present. Representative synthetic strategies are highlighted to illustrate the versatility of the indole framework in drug design. Furthermore, we systematically discuss each drug's pharmacology, mechanisms of action, and clinical applications. By integrating synthetic chemistry with clinical applications, this review aims to provide medicinal chemists and drug developers with guidance for leveraging indole scaffolds in next-generation therapeutic discovery and development.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2616556"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12854230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Over-expression, purification, and kinetic analysis of Mycobacterium tuberculosis WecA. 结核分枝杆菌WecA的过表达、纯化及动力学分析。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-01-08 DOI: 10.1080/14756366.2025.2610028

Yishu Zhao, Haiying Jia, Yan Wang, Shanshan Sha, Dong An, Shufeng Yang, Lei Qian, Yufang Ma, Liming Xu

{"title":"Over-expression, purification, and kinetic analysis of Mycobacterium tuberculosis WecA.","authors":"Yishu Zhao, Haiying Jia, Yan Wang, Shanshan Sha, Dong An, Shufeng Yang, Lei Qian, Yufang Ma, Liming Xu","doi":"10.1080/14756366.2025.2610028","DOIUrl":"10.1080/14756366.2025.2610028","url":null,"abstract":"The N-acetylglucosamine-1-phosphate transferase (WecA)is a potential target for developing anti-tuberculosis drugs, due to its critical role in the synthesis of mycobacterial cell wall. The enzymatic study of WecA and the discovery of WecA inhibitors are therefore justified. However, WecA is a membrane protein with 11 transmembrane domains, making it difficult to be obtained, and even more difficult to perform activity studies. In order to gain sufficient WecA protein for activity investigation, the Escherichia coli (E. coli) Lemo21(DE3) strain was utilised in this study. The expression level of WecA was precisely regulated by T7 lysozyme. Purified WecA was obtained by affinity chromatography and identified by mass spectrometry. The kinetic properties of WecA were determined based on the detection of the product UMP. In addition, tunicamycin proved to be a competitive inhibitor. These results will lay theoretical foundations for the elucidation of WecA catalytic mechanism and the development of WecA inhibitors.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2610028"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12784632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer. 结合虚拟筛选和分子动力学模拟鉴定大黄素作为PYCR1抑制剂调节前列腺癌中多西他赛的敏感性。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-02-10 DOI: 10.1080/14756366.2026.2622725

Shuai Liu, Yongfeng Lao, Long Cheng, Xi Xiao, Longtu Ma, Wenyun Wang, Kun Zhao, Wenxuan Li, Zhongze Zhou, Qingchao Li, Yan Tao, Shanhui Liu, Zhilong Dong

{"title":"Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer.","authors":"Shuai Liu, Yongfeng Lao, Long Cheng, Xi Xiao, Longtu Ma, Wenyun Wang, Kun Zhao, Wenxuan Li, Zhongze Zhou, Qingchao Li, Yan Tao, Shanhui Liu, Zhilong Dong","doi":"10.1080/14756366.2026.2622725","DOIUrl":"10.1080/14756366.2026.2622725","url":null,"abstract":"Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various cancers and promotes malignant progression, yet its role in DTX resistance in prostate cancer remains unclear. In this study, bioinformatics analyses and in vitro/vivo experiments demonstrated that interfering with PYCR1 expression modulates the sensitivity of prostate cancer cells to DTX. Subsequently, via structure-based virtual screening, molecular dynamics simulations, and cellular thermal shift assay (CETSA), emodin-an anthraquinone compound-was identified as a PYCR1-targeting agent. Collectively, these findings suggest that PYCR1 may serve as a key target mediating DTX resistance in prostate cancer, and the emodin-DTX combination provides a promising potential clinical strategy to overcome such resistance. Finally, its functions and safety were also verified through in vitro experiments.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2622725"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12893152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Solvent-controlled Rh-catalysed hydrodehalogenation and construction of phenanthridinone skeleton from a common precursor in one-step sequence and the antitumor activity of its derivatives. 溶剂控制铑催化一步法合成菲蒽醌骨架及其衍生物的抗肿瘤活性。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-07-28 DOI: 10.1080/14756366.2026.2704432

De-Xuan Hu, Chao Qin, Xiang Gao, Ling Tang, Yaxin Zheng, Rui Yin

{"title":"Solvent-controlled Rh-catalysed hydrodehalogenation and construction of phenanthridinone skeleton from a common precursor in one-step sequence and the antitumor activity of its derivatives.","authors":"De-Xuan Hu, Chao Qin, Xiang Gao, Ling Tang, Yaxin Zheng, Rui Yin","doi":"10.1080/14756366.2026.2704432","DOIUrl":"10.1080/14756366.2026.2704432","url":null,"abstract":"Herein, we report a solvent-controlled, operationally convenient and highly efficient rhodium(II)-catalysed protocol enabling hydrodehalogenation and phenanthridinone skeleton construction from 2-halobenzamide. This methodology facilitates the hydrodehalogenation of diverse 2-halobenzamides using isopropanol, providing quantitative yields without further purification. Furthermore, this strategy allows the direct and efficient conversion of 2‑halobenzamides into phenanthridinones by aprotic solvent. Additionally, a series of phenanthridinone derivatives were synthesised and evaluated for their inhibitory activities against tyrosyl-DNA phosphodiesterase 1 (TDP1) and topoisomerase IB (TOP1), as well as their cytotoxicity. Compound 3a showed potent TDP1 inhibitory activity (IC50 = 4.5 ± 0.4 μM) and synergistic effect with topotecan and radiosensitising effect in HCT116 cells by stabilising cellular TDP1 cleavage complexes (TDP1cc). Compound 3c exhibited strong TOP1 inhibition (+++) and induced the formation of cellular TOP1 cleavage complexes (TOP1cc) and DNA damage, and consequently triggered apoptosis. In vivo studies indicated that 3c exhibits antitumor efficacy in HCT116 xenograft model.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2704432"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13417644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diethyl Phthalate (DEP) as a potential osteosarcoma risk factor: a multi-omics study integrating network Toxicology, single-cell RNA sequencing, and molecular docking. 邻苯二甲酸二乙酯（DEP）作为潜在的骨肉瘤危险因素：一项整合网络毒理学、单细胞RNA测序和分子对接的多组学研究

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-02-16 DOI: 10.1080/14756366.2025.2611582

Shangqi Yin, Wuzheng Liu, Chunxiao Gao, Chunyan Li, Jun Wu

{"title":"Diethyl Phthalate (DEP) as a potential osteosarcoma risk factor: a multi-omics study integrating network Toxicology, single-cell RNA sequencing, and molecular docking.","authors":"Shangqi Yin, Wuzheng Liu, Chunxiao Gao, Chunyan Li, Jun Wu","doi":"10.1080/14756366.2025.2611582","DOIUrl":"10.1080/14756366.2025.2611582","url":null,"abstract":"Diethyl phthalate (DEP), a common plasticiser and endocrine disruptor, has been linked to cancer, but its role in osteosarcoma (OS) remains unclear. This study integrated network toxicology, transcriptomics, protein-protein interaction (PPI) analysis, machine learning, molecular docking, molecular dynamics (MD), single-cell RNA sequencing (scRNA-seq), and external validation to investigate DEP-related mechanisms in OS. We identified 45 DEP-responsive genes enriched in extracellular matrix-related pathways. PPI network analysis revealed 11 hub genes, of which LASSO, SVM-RFE, and Boruta algorithms consistently prioritised P4HA2, COL18A1, and COL10A1. Docking and MD simulations supported stable binding of DEP to P4HA2 and COL18A1 via hydrogen bonds and hydrophobic interactions. scRNA-seq demonstrated celltype-specific expression of these genes. Validation cohorts confirmed their upregulation in OS, with AUC values up to 0.950. These findings suggest that DEP may promote OS progression by targeting extracellular matrix remodelling, offering new diagnostic biomarkers and hypothesis-generating evidence for environmental osteocarcinogenesis.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2611582"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design, synthesis, and anti-inflammatory evaluation of novel analogues derived from the natural product reticuline. 从天然产物reticuline衍生的新型类似物的设计、合成和抗炎评价。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-06-04 DOI: 10.1080/14756366.2026.2682077

Yanyan Feng, Tong Li, Cheng Chen, Ziwei Tang, Zhouyan Liu, Chenglei Gu, Yang Pan, Jichao Chen

{"title":"Design, synthesis, and anti-inflammatory evaluation of novel analogues derived from the natural product reticuline.","authors":"Yanyan Feng, Tong Li, Cheng Chen, Ziwei Tang, Zhouyan Liu, Chenglei Gu, Yang Pan, Jichao Chen","doi":"10.1080/14756366.2026.2682077","DOIUrl":"10.1080/14756366.2026.2682077","url":null,"abstract":"The natural alkaloid reticuline exhibits promising anti-inflammatory activity in preclinical models; however, its development is hindered by moderate potency and limited accessibility. To overcome these hurdles, we developed an efficient synthetic route to reticuline, enabling the design and synthesis of 21 structural analogues. Through systematic structure-activity relationship (SAR) exploration, compound 10f was identified as a lead candidate, demonstrating potent anti-inflammatory effects coupled with low cytotoxicity in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. Mechanistic studies revealed that 10f suppressed the production of nitric oxide (NO), reactive oxygen species (ROS), and the pro-inflammatory cytokines TNF-α and IL-6. This anti-inflammatory effect was accompanied by the downregulation of iNOS and COX-2 expression and the inhibition of MAPK signalling pathway. Collectively, this work presents 10f as a promising anti-inflammatory lead compound and provides a rational strategy for the structural optimisation of natural product-inspired scaffolds.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2682077"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Discovery of a novel and potent KRAS^G12V-targeting peptide with antiproliferative activity against colorectal cancer cells. 发现一种新的有效的krasg12v靶向肽，具有抗结直肠癌细胞增殖活性。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-06-11 DOI: 10.1080/14756366.2026.2684700

Hai Zhang, Shudan Yang, Yuting Wang, Miao-Miao Niu, Jingjiang She

{"title":"Discovery of a novel and potent KRASG12V-targeting peptide with antiproliferative activity against colorectal cancer cells.","authors":"Hai Zhang, Shudan Yang, Yuting Wang, Miao-Miao Niu, Jingjiang She","doi":"10.1080/14756366.2026.2684700","DOIUrl":"10.1080/14756366.2026.2684700","url":null,"abstract":"Despite the clinical relevance of KRASG12V in colorectal cancer, KRASG12V-specific inhibitors remain limited. Through structure-based virtual screening of a 59,319-member peptide library, we identified four KRASG12V-targeting peptides, among which Peptide-1 showed the most favourable docking profile. MST assays confirmed Peptide-1 had the highest affinity among Peptides 1-4, with stronger binding to KRASG12V than to other KRAS mutants. Structural analysis, molecular dynamics simulations, and free-energy calculations indicated that Peptide-1 formed a stable and energetically favourable complex with KRASG12V through extensive hydrogen bonding and hydrophobic interactions. Peptide-1 showed favourable human serum stability and cellular NanoBRET-supported engagement with KRASG12V. Functionally, Peptide-1 displayed potent antiproliferative activity in colorectal cancer cell lines, weaker effects on normal cells and reduced efficacy after KRASG12V knockdown. In SW480 cells, Peptide-1 was associated with reduced ERK1/2 phosphorylation, p21 upregulation, and G0/G1 accumulation. Overall, these findings support further investigation of Peptide-1 as a KRASG12V-targeting peptide for colorectal cancer drug discovery.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2684700"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13262105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications. 纳米酶：桥接纳米级特性和催化机制，先进的生物医学应用。

IF 5.3 2区医学

Journal of Enzyme Inhibition and Medicinal Chemistry Pub Date : 2026-12-01 Epub Date: 2026-06-22 DOI: 10.1080/14756366.2026.2690829

Yunqin Sun, Yunchang Yang, Xinyao Kang, Yaofeng Wang

{"title":"Nanozymes: bridging nanoscale characteristics and catalytic mechanisms for advanced biomedical applications.","authors":"Yunqin Sun, Yunchang Yang, Xinyao Kang, Yaofeng Wang","doi":"10.1080/14756366.2026.2690829","DOIUrl":"10.1080/14756366.2026.2690829","url":null,"abstract":"Nanozymes-nanomaterials with intrinsic enzyme-like activity-have emerged as a transformative paradigm in biomedicine. Their catalytic proficiency is fundamentally dictated by unique nanoscale characteristics, particularly tuneable surface defects and geometric configurations. This review critically re-evaluates nanozyme catalytic mechanisms, precisely categorising them into reactive oxygen species (ROS)-generating pathways and electron-transfer processes. We highlight recent structural breakthroughs, emphasising the evolution from conventional nanoparticles to single-atom and dual-atom nanozymes (SANs/DANs) that exhibit unprecedented reaction kinetics. Furthermore, we synthesise their advanced applications across in vitro diagnostics, synergistic tumour therapy, antibacterial interventions, and regenerative medicine. Finally, we address current clinical translational bottlenecks and envision how artificial intelligence (AI)-guided rational design will shape the field's future. By bridging fundamental physical chemistry with clinical utility, this review provides a definitive mechanistic roadmap for deploying nanozymes in precision nanomedicine.","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":"41 1","pages":"2690829"},"PeriodicalIF":5.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13292316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0